HIV and Covid 19 Coinfection, A Local Perspective: A Retrospective Study from Qatar

Background : People living with HIV might be at an increased risk of SARS-CoV-2 infection or severe COVID-19 disease. In this report we aim to study patients with HIV/COVID 19 coinfection seen in Qatar and examine the effects of this coinfection on disease course and attempt to identify factors that may be associated with severe disease. We also attempt to compare our finding with that of a previous study conducted in Qatar in view of the emergence of new SARS CoV-2 variants and the widespread use of COVID 19 vaccine. Method : Review of the medical records of all HIV infected patients who developed COVID 19 infection during the period between 27 th February 2020 and 31 December 2022. Results : Among the 329 HIV infected patients who were living in Qatar during the study period we identified 136 patients with HIV/COVID 19 coinfection. 90 were Qatari and the rest were from other nationalities. 117 patients were males and 19 were females with a median age of 34 [IQR 28-59] years. 111 were known to be HIV infected before COVID 19 diagnosis and 25 were found to have HIV infection at the time of COVID 19 diagnosis or shortly after. 50 patients developed COVID 19 infection either before receiving SARS CoV-2 vaccine or in less than 14 days after the first vaccine dose and after a median of 246 days from last vaccine dose in the 86 vaccine recipients. Reinfection was relatively common occurring in about 9% of patients, however occurring after a median of 332 and 267 days from previous infection and last vaccine dose respectively. The disease was mild with hospital admission. There was no disease related mortality. Conclusion : The clinical manifestations of patients with HIV/COVID 19 coinfection seen in Qatar were similar to that reported by others, however, they were younger with male preponderance and is mostly mild to moderate in severity. Most infections occurred in the third year of the study (57%) when the Omicron variant was the predominant strain circulating in Qatar. Most infections occurred either in unvaccinated patients, within 14 days after the first dose or after a long period form the last vaccine dose. The outcome was excellent with no disease related mortality.

[1]  R. Iachan,et al.  Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[2]  Reed J. D. Sorensen,et al.  Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis , 2022, The Lancet.

[3]  K. Telle,et al.  Secondary Attack Rates for Omicron and Delta Variants of SARS-CoV-2 in Norwegian Households. , 2022, JAMA.

[4]  C. Scagnolari,et al.  Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report: Erratum , 2020, Medicine.

[5]  C. Agrati,et al.  COVID‐19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS‐CoV‐2 , 2020, Journal of medical virology.

[6]  C. Scagnolari,et al.  Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection , 2020, Medicine.

[7]  T. Kuno,et al.  Prognosis of coronavirus disease 2019 (COVID‐19) in patients with HIV infection in New York City , 2020, HIV medicine.

[8]  K. Bhaskaran,et al.  HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform , 2020, medRxiv.

[9]  B. Woodward,et al.  Coronavirus disease 2019 (COVID‐19) outcomes in HIV/AIDS patients: a systematic review , 2020, HIV medicine.

[10]  M. Peluso,et al.  Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus , 2020, The Journal of Infectious Diseases.

[11]  Jessica K De Freitas,et al.  Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[12]  W. Mcfarland,et al.  COVID-19 Among People Living with HIV: A Systematic Review , 2020, AIDS and Behavior.

[13]  C. Rice,et al.  Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses , 2020, bioRxiv.

[14]  R. López-Vélez,et al.  Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort , 2020, The Lancet HIV.

[15]  A. Okoh,et al.  COVID-19 Pneumonia in Patients With HIV: A Case Series , 2020, Journal of acquired immune deficiency syndromes.

[16]  M. Carrington,et al.  Predicting the Immunogenicity of T cell epitopes: From HIV to SARS-CoV-2 , 2020, bioRxiv.

[17]  Maomao Wang,et al.  One case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a low CD4+ T-cell count , 2020, International Journal of Infectious Diseases.

[18]  Felipe García,et al.  COVID-19 in patients with HIV: clinical case series , 2020, The Lancet HIV.

[19]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[20]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[21]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[22]  J. Aberg Aging, inflammation, and HIV infection. , 2012, Topics in antiviral medicine.

[23]  P. Boudes HIV infection in the elderly. , 1991, Comprehensive therapy.

[24]  N. Michael,et al.  Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.